OmniAb, Inc.

OmniAb, Inc. (NASDAQ: OABI) is a biotechnology company focused on antibody discovery technologies, providing transgenic animal platforms and AI-driven tools to biopharmaceutical partners developing novel therapeutics. The company became publicly traded in late 2022 through a merger with Avista Public Acquisition Corp. II, a blank-check vehicle sponsored by Avista Capital Partners that completed its IPO in 2021. Originally spun out of Ligand Pharmaceuticals, OmniAb operates in the life sciences tools and services sector and filed an 8-K with the SEC on June 21, 2024. The company continues to trade on Nasdaq under the ticker OABI following the completion of its de-SPAC transaction. Sign up at SpacDesk for full filing history, sponsor profiles, and post-merger performance data on OABI and hundreds of other SPAC deals.